On August 19, Agilent rose 5.02% in regular trading, trading at approximately $155.89/share, with turnover of $2.57 billion. The rally was driven by an optimistic earnings preview ahead of the company's upcoming quarterly report on August 26, combined with broad strength across the Life Sciences Tools and Services sector.

On the news front, market consensus estimates project Agilent's quarterly revenue at $18.41 billion, representing 10.57% year-over-year growth, with adjusted EPS expected at $1.49, up 8.80% year-over-year. Morgan Stanley recently raised its price target on Agilent to $175 from $160 while maintaining an Overweight rating, reflecting institutional confidence in the company's growth trajectory. Multiple brokerages maintain bullish outlooks on the stock.

Sector-wide momentum further amplified the move, with Tempus AI surging 22.71%, Illumina gaining 7.92%, and Danaher rising 6.06% during the session. The company has also seen a series of positive catalysts in recent months, including FDA and EU approvals expanding its PD-L1 diagnostic portfolio, the completion of its Biocare Medical acquisition strengthening its clinical diagnostics presence, and a strategic AI partnership with OpenAI and Boston Consulting Group.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)